{"id":79184,"date":"2026-09-07T12:23:51","date_gmt":"2026-09-07T04:23:51","guid":{"rendered":"https:\/\/flcube.com\/?p=79184"},"modified":"2026-09-07T12:23:52","modified_gmt":"2026-09-07T04:23:52","slug":"anglikang-pharmaceuticals-terminates-affinity-partnership-for-imd-1005-novel-tumor-microenvironment-activated-cd47-antibody","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=79184","title":{"rendered":"Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Anglikang Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/002940:SHE\">SHE: 002940<\/a>) announced that its partnership with <strong>Affinity<\/strong> for the <strong>IMD\u20111005<\/strong> project will be terminated. According to the termination notice sent by <strong>Affinity<\/strong>, and based on comprehensive considerations regarding its overall strategic layout and pipeline prioritization, the decision was made to independently advance the R&amp;D, manufacturing, and commercialization of <strong>IMD\u20111005<\/strong> in the agreed territories at this stage, rather than collaborating with third parties via out\u2011licensing.<\/p>\n\n\n\n<h2 id=\"h-transaction-milestone\" class=\"wp-block-heading\">Transaction Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Field<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Company<\/td><td><strong>Anglikang Pharmaceuticals<\/strong> (SHE: 002940)<\/td><\/tr><tr><td>Partner<\/td><td><strong>Affinity<\/strong><\/td><\/tr><tr><td>Asset<\/td><td><strong>IMD\u20111005<\/strong> \u2014 tumor microenvironment\u2011activated anti\u2011<strong>CD47<\/strong> antibody<\/td><\/tr><tr><td>Action<\/td><td>Partnership termination; <strong>IMD\u20111005<\/strong> project collaboration ends<\/td><\/tr><tr><td>Notice Source<\/td><td>Termination notice sent by <strong>Affinity<\/strong><\/td><\/tr><tr><td>Stated Rationale<\/td><td>Overall strategic layout and pipeline prioritization; independent advancement preferred over third\u2011party out\u2011licensing at this stage<\/td><\/tr><tr><td>Date<\/td><td>07 Sep 2026<\/td><\/tr><tr><td>Territory Implication<\/td><td><strong>Affinity<\/strong> to independently advance R&amp;D, manufacturing, and commercialization in the agreed territories<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>IMD\u20111005<\/strong>, developed by <strong>Affinity<\/strong>.<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>CD47<\/strong>, a key &#8220;don&#8217;t eat me&#8221; signal exploited by tumors to evade innate immune clearance.<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> A globally novel tumor microenvironment\u2011activated antibody design, intended to selectively engage within the tumor milieu.<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> The tumor microenvironment\u2011activation concept distinguishes <strong>IMD\u20111005<\/strong> from conventional anti\u2011<strong>CD47<\/strong> approaches in the immuno\u2011oncology landscape.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-licensing-agreement-background\" class=\"wp-block-heading\">Licensing Agreement Background<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Term<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agreement Date<\/td><td>August 2025<\/td><\/tr><tr><td>Parties<\/td><td><strong>Anglikang Pharmaceuticals<\/strong> and <strong>Affinity<\/strong><\/td><\/tr><tr><td>Structure<\/td><td>Exclusive in\u2011licensing agreement<\/td><\/tr><tr><td>Rights Acquired<\/td><td>Development, manufacturing, and commercialization rights<\/td><\/tr><tr><td>Territories<\/td><td>Mainland China, Hong Kong, Macao, and Taiwan<\/td><\/tr><tr><td>Total Commitment<\/td><td>Up to RMB 770 million<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Under the August 2025 licensing agreement, <strong>Anglikang Pharmaceuticals<\/strong> committed up to RMB 770 million to acquire the exclusive rights to develop, manufacture, and commercialize <strong>IMD\u20111005<\/strong> in Mainland China, Hong Kong, Macao, and Taiwan. The September 2026 termination notice from <strong>Affinity<\/strong> ends that collaboration, with <strong>Affinity<\/strong> opting to advance the <strong>CD47<\/strong> program independently in the agreed territories rather than continue via out\u2011licensing to third parties at this stage.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Reprioritization:<\/strong> The termination reflects <strong>Affinity<\/strong>&#8216;s comprehensive review of its strategic layout and pipeline prioritization, favoring independent control of the <strong>IMD\u20111005<\/strong> program.<\/li>\n\n\n\n<li><strong>Portfolio Effect for Anglikang:<\/strong> <strong>Anglikang Pharmaceuticals<\/strong> will no longer pursue <strong>IMD\u20111005<\/strong> under the 2025 in\u2011licensing framework; the company did not quantify financial implications in the announcement.<\/li>\n\n\n\n<li><strong>Asset Trajectory:<\/strong> The globally novel tumor microenvironment\u2011activated anti\u2011<strong>CD47<\/strong> antibody remains an active development asset, now advanced solely by <strong>Affinity<\/strong> in the agreed territories.<\/li>\n\n\n\n<li><strong>Sector Context:<\/strong> The move underscores continuing realignment in immuno\u2011oncology partnerships, where sponsors increasingly weigh internal advancement against out\u2011licensing as pipeline strategies evolve.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding the termination of the partnership between <strong>Anglikang Pharmaceuticals<\/strong> and <strong>Affinity<\/strong> and the future development of <strong>IMD\u20111005<\/strong>, including <strong>Affinity<\/strong>&#8216;s independent advancement of the tumor microenvironment\u2011activated <strong>CD47<\/strong> antibody. Such statements are based on current expectations and are subject to risks and uncertainties, including R&amp;D, regulatory review, and commercialization risks. Actual results may differ materially. Nothing herein constitutes investment advice or an offer to buy or sell any securities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/\u6602\u5229\u5eb7\uff1a\u5173\u4e8e\u7ec8\u6b62\u300a\u6218\u7565\u5408\u4f5c\u534f\u8bae\u4e4b\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u300b\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6602\u5229\u5eb7\uff1a\u5173\u4e8e\u7ec8\u6b62\u300a\u6218\u7565\u5408\u4f5c\u534f\u8bae\u4e4b\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u300b\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-44b529ae-3dda-450e-ba07-83b9e8e583d5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/\u6602\u5229\u5eb7\uff1a\u5173\u4e8e\u7ec8\u6b62\u300a\u6218\u7565\u5408\u4f5c\u534f\u8bae\u4e4b\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u300b\u7684\u516c\u544a.pdf\">\u6602\u5229\u5eb7\uff1a\u5173\u4e8e\u7ec8\u6b62\u300a\u6218\u7565\u5408\u4f5c\u534f\u8bae\u4e4b\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u300b\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/\u6602\u5229\u5eb7\uff1a\u5173\u4e8e\u7ec8\u6b62\u300a\u6218\u7565\u5408\u4f5c\u534f\u8bae\u4e4b\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u300b\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-44b529ae-3dda-450e-ba07-83b9e8e583d5\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD\u20111005 project will&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1539,16,1538],"class_list":["post-79184","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-anglikang-pharmaceutical","tag-cancer","tag-she-002940"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD\u20111005 project will be terminated. According to the termination notice sent by Affinity, and based on comprehensive considerations regarding its overall strategic layout and pipeline prioritization, the decision was made to independently advance the R&amp;D, manufacturing, and commercialization of IMD\u20111005 in the agreed territories at this stage, rather than collaborating with third parties via out\u2011licensing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=79184\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody\" \/>\n<meta property=\"og:description\" content=\"Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD\u20111005 project will be terminated. According to the termination notice sent by Affinity, and based on comprehensive considerations regarding its overall strategic layout and pipeline prioritization, the decision was made to independently advance the R&amp;D, manufacturing, and commercialization of IMD\u20111005 in the agreed territories at this stage, rather than collaborating with third parties via out\u2011licensing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=79184\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-07T04:23:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-07T04:23:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79184#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79184\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody\",\"datePublished\":\"2026-09-07T04:23:51+00:00\",\"dateModified\":\"2026-09-07T04:23:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79184\"},\"wordCount\":505,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Anglikang Pharmaceutical\",\"Cancer\",\"SHE: 002940\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=79184#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79184\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=79184\",\"name\":\"Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-07T04:23:51+00:00\",\"dateModified\":\"2026-09-07T04:23:52+00:00\",\"description\":\"Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD\u20111005 project will be terminated. According to the termination notice sent by Affinity, and based on comprehensive considerations regarding its overall strategic layout and pipeline prioritization, the decision was made to independently advance the R&D, manufacturing, and commercialization of IMD\u20111005 in the agreed territories at this stage, rather than collaborating with third parties via out\u2011licensing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79184#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=79184\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79184#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody - Insight, China&#039;s Pharmaceutical Industry","description":"Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD\u20111005 project will be terminated. According to the termination notice sent by Affinity, and based on comprehensive considerations regarding its overall strategic layout and pipeline prioritization, the decision was made to independently advance the R&D, manufacturing, and commercialization of IMD\u20111005 in the agreed territories at this stage, rather than collaborating with third parties via out\u2011licensing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=79184","og_locale":"en_US","og_type":"article","og_title":"Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody","og_description":"Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD\u20111005 project will be terminated. According to the termination notice sent by Affinity, and based on comprehensive considerations regarding its overall strategic layout and pipeline prioritization, the decision was made to independently advance the R&D, manufacturing, and commercialization of IMD\u20111005 in the agreed territories at this stage, rather than collaborating with third parties via out\u2011licensing.","og_url":"https:\/\/flcube.com\/?p=79184","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-07T04:23:51+00:00","article_modified_time":"2026-09-07T04:23:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=79184#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=79184"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody","datePublished":"2026-09-07T04:23:51+00:00","dateModified":"2026-09-07T04:23:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=79184"},"wordCount":505,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Anglikang Pharmaceutical","Cancer","SHE: 002940"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=79184#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=79184","url":"https:\/\/flcube.com\/?p=79184","name":"Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-07T04:23:51+00:00","dateModified":"2026-09-07T04:23:52+00:00","description":"Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD\u20111005 project will be terminated. According to the termination notice sent by Affinity, and based on comprehensive considerations regarding its overall strategic layout and pipeline prioritization, the decision was made to independently advance the R&D, manufacturing, and commercialization of IMD\u20111005 in the agreed territories at this stage, rather than collaborating with third parties via out\u2011licensing.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=79184#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=79184"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=79184#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD\u20111005, Novel Tumor Microenvironment\u2011Activated CD47 Antibody"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=79184"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79184\/revisions"}],"predecessor-version":[{"id":79188,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79184\/revisions\/79188"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=79184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=79184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=79184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}